Anzeige
❌
Mehr »
Donnerstag, 19.11.2026 - Börsentäglich über 12.000 News
Folge dem Geld: Methan im Fokus der COP31!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PA

WKN: A2DTAT | ISIN: SE0009806284 | Ticker: B0F
Frankfurt
18.11.26 | 08:57
5,870 Euro
+0,86 % +0,050
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
PAXMAN AB Chart 1 Jahr
5-Tage-Chart
PAXMAN AB 5-Tage-Chart
RealtimeGeldBriefZeit
5,9205,98018.11.

Aktuelle News zur PAXMAN Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
30.10.Paxman AB: Paxman Secures First UK Orders for Neuropathy System Ahead of Commercial Launch to Address the Significant Unmet Clinical Need of Chemotherapy-Induced Peripheral Neuropathy (CIPN)257This initial commitment from a major global healthcare group marks a key commercial milestone for Paxman's first expansion beyond scalp cooling into chemotherapy side effect management The orders represent...
► Artikel lesen
21.08.Paxman: Quartalsumsatz übertrifft erstmals 100 Mio. SEK - Aktie legt um 15 % zu1
21.08.Paxman Aktie steigt um 15 % nach Rekordumsatz im zweiten Quartal 2026, der erstmals 100 Mio. SEK übersteigt1
21.08.Paxman AB: PAXMAN publishes its interim report for Q2 2026355Paxman breaks the 100 MSEK barrier for the first time in a record-breaking Q2! Figures in parentheses refer to the outcome for the corresponding period of the previous year. Dignitana has been part...
► Artikel lesen
10.08.Paxman AB: Paxman Announces FDA Regulatory Progress for Limb Cryocompression System288Paxman today announces a significant regulatory milestone in the development of its Limb Cryocompression System for the reduction of chemotherapy-induced peripheral neuropathy (CIPN), with the U.S....
► Artikel lesen
22.05.Paxman AB: Press release from PAXMAN AB's 2026 Annual General Meeting466PAXMAN's AGM was held today, 22 May 2026, in Karlshamn. Almost 36,4 % of all issued shares were represented at the meeting. After the formal AGM, CEO Richard Paxman gave a digital company presentation...
► Artikel lesen
21.05.Paxman AB: PAXMAN publishes its interim report for Q1 2026302Figures in parentheses refer to the outcome for the corresponding period of the previous year. Dignitana has been part of the group since June 1 2025. The Group's sales amounted to 89.6 (67.1) MSEK...
► Artikel lesen
27.02.Paxman AB: PAXMAN publishes year-end report as of 31 December 2025970Strategic investments support future growth! Figures in parentheses refer to the outcome for the corresponding period of the previous year.The Group's net sales amounted to 84.4 (66.2) MSEK for the...
► Artikel lesen
PAXMAN Aktie jetzt für 0€ handeln
20.02.Paxman AB: Paxman Announces Category III CPT Codes for Cryocompression Therapy to Prevent Chemotherapy-Induced Peripheral Neuropathy863Paxman, the global leader in cancer side effect management, today announced that the American Medical Association (AMA) CPT Editorial Panel has established three Category III CPT® codes describing the...
► Artikel lesen
9 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1